Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer-Reference-Cited by-同舟云学术

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Published:2018-05-04 Issue:1 Volume:4 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Stover Daniel G.^ORCID,Gil Del Alcazar Carlos R.,Brock Jane,Guo Hao,Overmoyer Beth,Balko Justin,Xu Qiong,Bardia Aditya,Tolaney Sara M.,Gelman Rebecca,Lloyd Maxwell,Wang Yu,Xu Yaomin,Michor Franziska,Wang Vivian,Winer Eric P.,Polyak Kornelia,Lin Nancy U.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-018-0060-z.pdf

Reference33 articles.

1. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721–1728 (2007).

2. Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463–5472 (2012).

3. Lin, N. U. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113, 2638–2645 (2008).

4. Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9, 29–33 (2009).

5. Rugo, H. S. et al. San Antonio Breast Cancer Symposium (San Antonio, TX, 2017).

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate;Acta Crystallographica Section C Structural Chemistry;2024-07-24

2. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1;Molecular Biology Reports;2024-07-22

3. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer;European Journal of Medicinal Chemistry;2024-07

4. Molecular pathways and targeted therapies in head and neck cancers pathogenesis;Frontiers in Oncology;2024-06-17

5. Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification;BMC Cancer;2024-06-13